Join to view full profile
1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-930-5446
Dr. Salhotra is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Amandeep Salhotra is an oncologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from Maulana Azad Medical College and has been in practice 18 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
University of Virginia Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2012
Boston Medical Center-BrightonFellowship, Hematology and Medical Oncology, 2009 - 2010- Boston Medical Center-BrightonResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 1999
Certifications & Licensure
CA State Medical License 2012 - 2028
VA State Medical License 2010 - 2012
MA State Medical License 2009 - 2011
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
- CMS Meaningful Use Stage 2 Certification Sunrise Acute Care, Allscripts, 2013-2017
Clinical Trials
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation Start of enrollment: 2019 Dec 23
- Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Start of enrollment: 2020 May 12
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Roles: Contact
Publications & Presentations
PubMed
- CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL.Vaibhav Agrawal, Haoyue Shan, Monzr Al Malki, Amandeep Salhotra, Ahmed Aribi
Transplantation and Cellular Therapy. 2026-10-03 - Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.Tamer Othman, Vaibhav Agrawal, Joo Y Song, Zhaohui Gu, Paul Koller
American Journal of Hematology. 2026-10-01 - 1 citationsCAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.Ibrahim Aldoss, Lior Goldberg, Jianying Zhang, Andrew Artz, Mary C Clark
Blood Advances. 2026-09-08
Abstracts/Posters
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
Press Mentions
From Novel Therapies to First-in-Human Trials, City of Hope Advances Blood Cancer Care at the American Society of Hematology (ASH) Annual ConferenceDecember 8th, 2025- City of Hope to Present Breakthroughs in Blood Cancer, Microbiome Research and Cellular Therapies at ASH 2025December 7th, 2024
- Plerixafor Doesn’t Overcome HPC Failure in R-hyperCVAD for Mantle Cell LymphomaSeptember 10th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: